Atherosclerosis, cigarette smoking, and endogenous fibrinolysis: is there a direct link?

Stanley Chia1, David E Newby

  • 1Department of Cardiology, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW, United Kingdom. schia@ed.ac.uk

Insights

Atherosclerosis and smoking impair the body's ability to release tissue plasminogen activator (tPA), a key factor in dissolving blood clots. This reduction in tPA may explain how these conditions worsen coronary artery disease complications.

Area of Science:

  • Cardiovascular Science
  • Thrombosis and Hemostasis
  • Endothelial Biology

Background:

  • Acute myocardial infarction results from coronary artery blockage by blood clots.
  • Endothelial function and tissue plasminogen activator (tPA) are crucial for maintaining blood flow.
  • Atherosclerosis and smoking are linked to endothelial dysfunction.

Purpose of the Study:

  • To investigate the impact of atherosclerosis and cigarette smoking on endogenous fibrinolytic activity.
  • To explore the role of impaired tPA release in the pathogenesis of coronary artery disease.

Main Methods:

  • The study focuses on the physiological mechanisms underlying acute myocardial infarction.
  • It examines the relationship between endothelial function, tPA release, and thrombotic complications.
  • The research analyzes how atherosclerosis and smoking affect local fibrinolytic capacity.

Main Results:

  • Atherosclerosis and cigarette smoking are associated with impaired endothelial function.
  • These conditions appear to reduce the acute, local release of endogenous tissue plasminogen activator (tPA).
  • Reduced tPA capacity may contribute to the initiation and progression of thrombotic events in coronary artery disease.

Conclusions:

  • Impaired endothelial release of tPA due to atherosclerosis and smoking is a significant factor in coronary artery disease.
  • This mechanism highlights how these risk factors can exacerbate acute and chronic thrombotic complications.
  • Restoring or enhancing tPA function could be a therapeutic target for managing coronary artery disease.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...